GlassScriptPhysician profile
Mark Phillip Siegel
NPI 1487690046
$2,043.29
in general payments reported to CMS, 2019-2025
27 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $261 · 2021: $278 · 2022: $311 · 2023: $101 · 2024: $468 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $440.10 | 2021-2025 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.14 | 2019-2024 | Xifaxan, Trulance |
| Antares Pharma, INC. | $296.22 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Astrazeneca Pharmaceuticals LP | $196.06 | 2019-2025 | Airsupra |
| Abbott Laboratories | $73.35 | 2022 | |
| Life Spine, INC. | $67.14 | 2022 | |
| Clarus Therapeutics INC. | $66.48 | 2021 | |
| Acerus Pharmaceuticals Corporation | $63.18 | 2021-2022 | |
| Horizon Therapeutics Plc | $54.74 | 2020 | |
| Protega Pharmaceutials INC | $50.67 | 2024 | Roxybond |
| Idorsia Pharmaceuticals US INC | $29.69 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.69 | 2021 | |
| Tolmar, INC. | $25.08 | 2023 | |
| Spinal Simplicity, LLC | $24.14 | 2022 | |
| Edwards Lifesciences Corporation | $23.60 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.39 | 2024 | Evenity, Prolia |
| Lucid Diagnostics INC. | $20.19 | 2022 | |
| Boston Scientific Corporation | $18.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.46 | 2022 | |
| Abbvie INC. | $17.73 | 2020 | |
| Globus Medical, INC. | $17.40 | 2025 | Senza |
| Eisai INC. | $16.94 | 2021 | |
| Hikma Pharmaceuticals USA | $16.71 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.71 | 2021 | |
| Verity Pharmaceuticals INC. | $15.33 | 2025 | Tlando |
| Teleflex LLC | $15.30 | 2021 | |
| Novo Nordisk INC | $15.02 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.